Connect with us

Hi, what are you looking for?

Sunday, Dec 3, 2023
Mugglehead Magazine
Alternative investment news based in Vancouver, B.C.

The weed wire

Tetra Bio Pharma hires pediatric meds exec as president

Sylvain Chrétien was president of Pediapharm and Medexus for 12 years

WeedMD acquires another union medical supply agreement

Cannabis-derived treatment developer Tetra Bio Pharma Inc. (TSX-V:TBP and OTCQB: TBPMF) is building out its top management with the addition of a new president.

The company announced Tuesday that Sylvain Chrétien, the long-time former top boss of Pediapharm, which a year ago rebranded to Medexus, would be joining Tetra as its new president.

The company’s stock remained stable after the announcement at around $0.42 per share on Tuesday.

Chrétien will report directly to CEO Guy Chamberland, who Tetra said was instrumental in selecting the company’s first president.

The additional role will allow Chamberland to devote more time to regulatory strategies and drug development of CAMUZ, QIXLEEF and HCC011, the company said, which are mostly cannabis-derived treatments for pain management of advanced cancers.

Read more: U.S. FDA gives rare designation to THC cancer drug in clinical trials

Read more: Health Canada approves two Tetra Bio Pharma topicals for over-the-counter sales

As Tetra moves closer to commercializing its pharmaceutical roster, Chrétien will be responsible for investor relations and bringing products to market.

As CEO of Medexus Chrétien oversaw the company’s development of various drugs, including pediatric treatments for head lice and seasonal allergies.

While Medexus has shown strong revenue growth in recent years, some have raised concerns over high levels of debt.

In Tuesday’s press release, Chamberland expressed his excitement at Chrétien joining their executive team.

“I am thrilled to welcome Sylvain to our senior executive team at this exciting time. He brings with him decades of experience and a deep understanding of the biopharmaceutical industry, along with a proven track record of successful leadership in managing growth,” the Pharma CEO said. “We look forward to his contributions as we continue to deliver on our strategy and transform to a fully integrated biopharmaceutical company.”

“I am honored to join Dr. Chamberland and the entire team of Tetra as they work to develop QIXEEF and CAUMZ for patients with advanced cancer pain,” Chrétien said.

Top photo via Deposit Photos


Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like


The survey results follow the city of Berkeley decriminalizing psychedelic plants and fungi on Tuesday


'We have a big team behind us and we have a lot of people supporting us' said the store's co-owner on Thursday


New phase I study will be held at MAC Clinical Research in Manchester, England next year


Canadian company set to focus clinical trials down under, announces regulatory update